首页|TEL-AML1融合基因在儿童急性淋巴细胞白血病中的表达及对其疗效及预后的影响

TEL-AML1融合基因在儿童急性淋巴细胞白血病中的表达及对其疗效及预后的影响

扫码查看
目的 探讨TEL-AML1融合基因在儿童急性淋巴细胞白血病中的表达及对其疗效及预后的影响.方法 收集儿童急性淋巴细胞白血病106例,应用巢式PCR技术检测TEL-AML1基因表达,根据TEL-AML1基因是否表达,分为TEL/AML1+组、TEL/AML1-组.结果 两组患儿年龄、发热率比较,差异有统计学意义(P<0.05),两组患儿其他临床特征比较,差异无统计学意义(P>0.05).TEL/AML1+组与TEL/AML1-组临床疗效比较,差异具有统计学意义(x2=7.617,P=0.022).第12周MRD水平可能为TEL-AML1融合基因阳性儿童急性淋巴细胞白血病患者预后的影响因素(P<0.05).结论 TEL-AML1融合基因阳性儿童急性淋巴细胞白血病患儿生存率更高,第12周MRD水平可能是影响患儿预后因素.
The Expression of TEL-AML1 Fusion Gene in Children with Acute Lymphoblastic Leukemia and Its Influence on the Curative Effect and Prognosis
Objective To investigate the expression of TEL-AML1 fusion gene in children with acute lymphoblastic leu-kemia(AML)and its effect on its efficacy and prognosis.Methods 106 children with acute lymphoblastic leukemia were collect-ed and the TEL-AML1 gene expression was detected by nested PCR.According to the expression of TEL-AML1 gene,they were divided into TEL/AML1+group and TEL/AML1-group.Results There were statistically significant differences in age and fe-ver rate between the 2 groups(P<0.05),but no statistically significant differences in other clinical characteristics between the 2 groups(P>0.05).There was significant difference in clinical efficacy between TEL/AML1+group and TEL/AML1-group(x2=7.617,P=0.022).MRD level at week 12 May be a prognostic factor of TEL-AML1 fusion gene positive in children with a-cute lymphoblastic leukemia(P<0.05).Conclusion The survival rate of children with TEL-AML1 fusion gene positive acute lymphoblastic leukemia is higher,and the level of MRD at week 12 may be a prognostic factor.

Acute lymphocytic leukemiaTEL-AML1 fusion geneEfficacyPrognosis

陈静、史利欢、谢昕、范鹏凯、许哲

展开 >

450018 郑州大学附属儿童医院,河南省儿童医院

急性淋巴细胞白血病 TEL-AML1融合基因 疗效 预后

河南医学科技攻关计划联合共建项目

LHGJ2022-0742

2024

实用癌症杂志
江西省肿瘤医院 江西省肿瘤研究所

实用癌症杂志

影响因子:1.241
ISSN:1001-5930
年,卷(期):2024.39(6)